Background: T H 2 cell-released IL-31 is a critical mediator in patients with atopic dermatitis (AD), a prevalent and debilitating chronic skin disorder. Brain-derived natriuretic peptide (BNP) has been described as a central itch mediator. The importance of BNP in peripheral (skin-derived) itch and its functional link to IL-31 within the neuroimmune axis of the skin is unknown. Objective: We sought to investigate the function of BNP in the peripheral sensory system and skin in IL-31-induced itch and neuroepidermal communication in patients with AD. Methods: Ca 21 imaging, immunohistochemistry, quantitative real-time PCR, RNA sequencing, knockdown, cytokine/phosphokinase arrays, enzyme immune assay, and pharmacologic inhibition were performed to examine the cellular basis of the IL-31-stimulated, BNP-related itch signaling in dorsal root ganglionic neurons (DRGs) and skin cells, transgenic AD-like mouse models, and human skin of patients with AD and healthy subjects.
Atopic dermatitis (AD) is one of the most prevalent chronic inflammatory skin diseases worldwide. It is characterized by dysregulation of immunity and skin barrier and nerve function, resulting clinically in eczema and itch. [1] [2] [3] [4] The mediators of histamine-independent itch in patients with AD are poorly understood. 5 Candidates include endothelin-1 (ET-1), thymic stromal lymphopoietin, and the cytokines IL-4, IL-13, and IL-31.
1 IL-31 is a critical cytokine in the pathophysiology of AD, 1, 6, 7 playing a role in eczema, 7 itch, 8 and nerve growth. 9 Increased serum levels of IL-31 were found to correlate with disease severity in patients. 6 ,10 IL-31 serves as a critical neuron-immune link between T H 2 cells and sensory nerves in the generation of T cell-mediated itch. 8 Cutaneous and intrathecal injections of IL-31 evoked robust itch behavior in mice. 8 IL-31 injection in the mouse cheek induces itch but not pain. 8 IL-31 transgenic (Tg) mice that overexpress IL-31 have severe pruritus and skin lesions similar to AD. 7 In mice IL-31 receptor A (IL-31RA) associates with oncostatin M Targeting the IL-31 pathway therapeutically has proved effective in patients with AD. 11, 12 For example, IL-31 neutralization in AD models was effective in the treatment of IL-31-induced itch and dermatitis. [13] [14] [15] [16] [17] The anti-IL-31RA antibody nemolizumab was evaluated in a phase II study with satisfactory efficacy and safety for the treatment of patients with moderate-tosevere AD. 11 Despite this, it is not known whether IL-31 stimulates neuropeptide release from central and/or peripheral primary afferent neurons to modulate itch transmission in the skin, spinal cord, or both. The importance of IL-31 in the regulation and release of neuropeptides from peripheral sensory nerves in the skin and the resulting neurogenic inflammation in patients with AD also remains elusive.
Brain-derived natriuretic peptide (BNP) is a 32-amino-acid cyclic peptide expressed in a subset of primary afferent neurons. [18] [19] [20] It binds to natriuretic peptide receptor A (NPR1) and, to a lesser extent, natriuretic peptide receptor B (NPR2). 21 BNP is the Nppb gene product and has been identified as an important neuropeptide for itch transmission from the sensory level to the spinal cord. 19 Intrathecal injection of BNP in mice induced a robust itch phenotype, whereas Nppb 2/2 mice exhibited lack of scratching responses to many pruritogens. 19 In contrast to substance P (SP) and calcitonin gene-related peptide (CGRP), which facilitate pain processing and painful neurogenic vasodilation in mice, BNP has been characterized as a negative regulator of nociceptive transmission. 20, 22 Nppb has been detected in the murine primary pruritogenic sensory dorsal root ganglionic neurons (DRGs), which overlapped with IL-31RA 1 neurons. 23 Despite its importance in itch, it is unknown whether BNP can be released from peripheral sensory neurons in response to pruritogens (ie, IL-31 or histamine). The cellular and molecular basis for its pruritic action on skin and immune cells also remains unknown. Understanding the downstream signaling pathways of IL-31 and its potential interacting mediators, such as BNP, CGRP, or SP, is significant because it will not only expand our current knowledge and theoretical repertoire but might also aid in the development of a more efficacious treatment for chronic skin inflammation and pruritus.
Here we investigated the possible mechanistic relationship between IL-31 and BNP in itch. The aim of the current study was to (1) examine the expression and function of IL-31 receptor in human dorsal root ganglionic neurons (hDRGs); (2) investigate the role of BNP in patients with AD by using mice models and human subjects; (3) investigate IL-31-induced release of BNP and other neuropeptides in relation to itch; (4) dissect the molecular components of the exocytotic machinery in IL-31-induced BNP release; (5) study the alteration of BNP receptor in AD skin; and (6) screen distinct intracellular kinases activated and cytokines induced by BNP in human skin cells. Overall, our results reveal a novel IL-31-mediated downstream target in itch induction and highlight the importance of BNP as a potential target for the treatment of AD and other itch disorders.
METHODS Materials
Human skin samples from 3 donors with AD and 3 healthy control donors were bought from Tissue Solutions (Glasgow, United Kingdom). hDRG paraffin sections were purchased from Amsbio (local distributor of Zyagen Laboratories, San Diego, Calif). Antibodies, cells, and reagents for tissue culture and others are detailed in the Methods section in this article's Online Repository at www.jacionline.org.
Human and animal rights
hDRGs were isolated, as previously described, 24 with full legal consent by Anabios (San Diego, Calif). DRGs were isolated and cultured from 1 donor, a 25-year-old Hispanic woman. Housing/handling of mice (C57BL6), IL-31Tg mice, and experimental procedures were approved by the University College Dublin Ethics Committee and the Irish Authorities. Housing/handling of the Grhl3PAR2 /1 Tg mouse model and experimental procedures following federal guidelines were approved by the University of California, the San Francisco Ethics Committee, and local authorities.
House dust mite application for the Grhl3PAR2 /1 mouse model
Grhl3PAR2
/1 mice were maintained in C57BL6/J-129X1/SvJ mixed strain and used for the experiments as an AD model. For details of house dust mite (HDM) treatment, see the Methods section in this article's Online Repository.
RNA sequencing
For gene expression experiments, trigeminal ganglia (TGs) were harvested from wild-type (WT) and HDM-treated Grhl3PAR2 /1 mice and processed for RNA sequencing (RNA-Seq). For details, see the Methods section in this article's Online Repository.
Quantitative real-time PCR
RNA was isolated from cultured mouse DRGs (mDRGs) by using the RNeasy kit (Qiagen, Hilden, Germany). TRIzol Reagent was used to isolate RNA from dorsal root ganglions and the skin of WTand IL-31Tg mice. mRNA quantitation was performed by using real-time fluorescence detection with the SYBR Green ROX mix (ABI). For details, see the Methods section in this article's Online Repository.
BNP, CGRP, and SP release assays
For detailed preparation of mDRG culture and neuropeptide release, see the Methods section in this article's Online Repository.
Measurement of intracellular Ca 21 concentration
hDRGs and mDRGs in culture were loaded with calcium indicator before measurement of Ca 21 mobilization in response to various pruritogens. For details, see the Methods section in this article's Online Repository.
Immunofluorescence staining
Cultured mDRGs, paraffin-embedded sections of hDRGs, and skin samples (15 mm) were stained and imaged with a Zeiss LSM710 confocal microscope (Carl Zeiss MicroImaging, Oberkochen, Germany). For details, see the Methods section in this article's Online Repository.
Lentivirus-mediated knockdown of soluble Nethylmaleimide-sensitive factor activating protein receptors mDRGs cultured for 7 days in vitro were treated with nontargeted control lentiviral particles or short hairpin RNA (shRNA) lentivirus specifically targeting soluble N-ethylmaleimide-sensitive factor activating protein receptors (SNAREs) for 7 to 10 days before measuring BNP release and protein expression. For details, see the Methods section in this article's Online Repository.
Culture of human primary epidermal keratinocytes and human monocyte-derived dendritic cells, cytokine antibody arrays, and phosphokinase arrays Human primary keratinocytes (hKCs) were cultured in KBM-Gold medium with KBM-Gold SingleQuot KC supplement (Lonza, Basel, Switzerland). Human dendritic cells (hDCs) were cultured by means of in vitro differentiation of CD14
1 monocytes with LGM-3 Lymphocyte Growth Medium plus 50 ng/ mL GM-CSF and 50 ng/mL IL-4 (Lonza). Cells were maintained in the above medium for 3 days before use. For detailed cytokine antibody and phosphokinase arrays, see the Methods section in this article's Online Repository.
Statistical data analysis
Data are expressed as means 6 SEMs (n > _ 3 independent experiments). P values were determined by using the Student 2-tailed t test; P values of less than .05 are considered significant. Data analysis was performed with Prism software (GraphPad Software, La Jolla, Calif).
RESULTS

IL-31RA and OSMRb are coexpressed in a small subset of hDRGs
In human patients with AD, IL-31 levels correlate with disease severity. 6, 10 However, subpopulations responding to IL-31 and distribution of its receptors (IL-31RA and OSMRb) in hDRGs have not been fully characterized. Our study will help define the functional contribution of neuronal subpopulations to the skin inflammation seen in patients with AD.
Using double immunohistochemistry, we observed IL-31RA and OSMRb expression in hDRG sections (Fig 1, A-D) . IL-31RA was detected in approximately 3% of total neurons visualized with the neuronal marker neuronal nuclei (NeuN) antibody, which stained strongly neuronal nuclei and distal cytoplasm (Fig 1, A) . IL-31RA also occurred in a small proportion of cells immunoreactive to protein gene product 9.5 (PGP9.5) antibody (Fig 1, B) , another marker for sensory nerves. Similarly, OSMRb was found in a small subset of PGP9.5
1 neurons (Fig 1, C) . Costaining of IL-31RA and OSMRb confirmed that in hDRGs all of the IL-31RA 1 neurons were OSMRb 1 (Fig 1, D and E) . However, approximately 5% of OSMRb 1 neurons did not appear to be strongly labeled by anti-IL-31RA (Fig 1, D, arrowed neuron) .
IL-31 induces intracellular calcium mobilization in a distinct subset of hDRGs, which also respond to ET-1
Functional identities of neuronal subsets were further assayed in hDRGs by using intracellular Ca 21 imaging on application of individual or combined pruritogens to cultured hDRGs. We found that approximately 4% of hDRGs were activated directly by ET-1 (n 5 100 neurons; Fig 2, A and B, top panels). The response consisted of a transient increase in intracellular calcium levels. In comparison, glial cells consistently exhibited large responses with slow kinetics. In several cases after ET-1 application, glial cells generated oscillatory calcium signals that persisted even after ET-1 washout (Fig 2, A and B , top panels). In our observation, approximately 50% of neurons pre-exposed to ET-1 also responded to histamine (Fig 2, A, middle panel, and C). After application of ET-1 and histamine, some neurons exhibited spontaneous calcium transients. Coapplication of ET-1 and histamine did not potentiate the response. On the contrary, desensitization was apparent in some neurons (Fig 2, A, bottom panel) . For the IL-31-induced response, 1 of 50 neurons pre-exposed to ET-1 responded with a rapid calcium transient to IL-31 (Fig 2, B , top and middle panels). Likewise, coapplication of ET-1 and IL-31 did not potentiate the response, except in one neuron with a delayed response (Fig 2, B, bottom panel) .
In summary, approximately 50% of neurons responded to histamine and approximately 4% of total neurons responded to ET-1. Half of the ET-1-responsive neurons also responded to histamine (Fig 2, C) . Overall, in hDRGs 2% of neurons responded to IL-31, and these cells also responded to ET-1 (Fig 2, C) . Because of the importance of IL-31 and ET-1 in the pathogenesis of AD, it is tempting to postulate that this neuronal subset mediates itch transmission in human subjects.
We investigated further whether mDRGs exhibit similar phenomena in response to IL-31 and ET-1. Cultured mDRGs uploaded with Fluo-4 AM were treated with IL-31 and ET-1 sequentially. In a total of 335 neurons recorded, IL-31 activated 9 neurons (approximately 2.7%), and ET-1 activated 14 neurons (approximately 4.2%). Five IL-31-responsive neurons did not respond to ET-1 (Fig 2, D) . Thus both similarities and differences were observed between hDRGs and mDRGs with respect to IL-31 and ET-1 stimulation.
PAR2Tg mice treated with HDM and IL-31Tg mice are associated with Nppb upregulation in sensory nerves
We investigated the possible involvement of BNP in patients with AD by using Grhl3PAR2 /1 mice. 25 These mice J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 5 have atopic-like inflammation, scaly dry skin, epidermal hyperplasia, and itch behaviors, all characteristics of human AD. 25 We applied HDM on the right cheek to induce severe dermatitis because HDMs have abundant proteases that can activate PAR2 constantly and stably. Ipsilateral and contralateral TGs from each mouse were analyzed by using RNA-Seq (Fig 3, A) . Clinical scores for pathologic diagnosis (skin lesion severity) were evaluated by using hematoxylin and eosin (H&E) staining on cheek skin biopsy specimens from each of the 8 HDM-applied mice and vehicle-treated WT mice (representative images shown in Fig 3, B) . Notably, in HDM-treated mice the correlation coefficient between clinical score and fold change of fragments per kilobase of transcript per million mapped reads (FPKM) for Nppb transcripts (ipsilateral/contralateral) is about 0.8 (Fig 3,  A) . The average fold change of Nppb for these 8 mice is approximately 2.3. In contrast, HDM did not induce significant changes in TGs for NPR1, NPR2, IL-31, IL-31RA, and OSMR in Grhl3PAR2 /1 mice (Fig 3, A) . After comparing FPKM from TGs of ipsilateral (right cheek) versus contralateral (left cheek) in 3 Grhl3PAR2 /1 mice with high clinical scores (scores were 8, 7, and 7, respectively), we found that Nppb transcripts were upregulated by 3.5 times by mean of application of HDM and ranked the third position among the highly upregulated genes (Fig 3, C) . Because IL-31Tg mice show skin phenotypes closely resembling those of human AD, 7 we used RT-PCR to compare Nppb transcripts in whole DRG tissue isolated from IL-31Tg skin (Fig 1, A) or PGP9.5 (Fig 1, B) . C, Costaining of OSMRb with PGP9.5 in hDRG sections. D, Immunofluorescence staining of hDRG sections showing IL-31RA and OSMRb largely colocalized in a subset of neurons. Specimens were counterstained with 49,6-diamidino-2-phenylindole (DAPI) to highlight all cell nuclei. The arrow indicates a neuron expressing OSMRb but not stained strongly by IL-31RA antibody. E, Venn diagram depicting the relationship of IL-31RA
(both lesional and nonlesional) and skin from age-matched WT nontransgenic mice. Higher levels of Nppb mRNA were detected in DRGs isolated from both lesional and nonlesional IL-31Tg mice (Fig 3, D) . Collectively, our data indicate that BNP is implicated in patients with AD and might be associated with the severity of AD-like skin conditions in mice.
IL-31 augments release and upregulates synthesis of BNP but not CGRP or SP from cultured mDRGs IL-31 directly activates peripheral sensory neurons to induce pruritus 8 ; however, its effect on BNP has not yet been reported. To explore this possibility, we cultured mDRGs and incubated neurons with 300 nmol/L IL-31 for 30 minutes for BNP release. IL-31-induced release was compared with the response to histamine and high-potassium (60 mmol/L) and low-potassium (3.5 mmol/L) chloride buffers (Fig 4, A) . Notably, IL-31 elicited an approximately 2.7-fold increase in BNP release over the basal level (low potassium). Histamine and potassium depolarization (high potassium) also elicited BNP release (Fig 4, A) . Moreover, IL-31-induced BNP release was concentration (Fig 4, B) and time (Fig 4, C) dependent. No significant difference in BNP release (Fig 4, B) and mRNA synthesis over 30 minutes (see Fig  E2, A, in this article's Online Repository at www.jacionline.org) was detected at IL-31 concentrations of between 300 nmol/L and 1 mmol/L. RT-PCR results revealed that 300 nmol/L IL-31-induced Nppb mRNA synthesis peaked at 4 hours and decreased at 8 hours (see Fig E2, B) . In contrast, neither CGRP nor SP release was affected by IL-31 or histamine, although both were elicited by high potassium (Fig 4, D) . For the first time, this finding demonstrates that IL-31 directly activates sensory neurons to release BNP rather than CGRP or SP. Consistently, incubation of mDRGs with IL-31 for 6 hours did not induce significant changes in mRNA levels of Calca (CGRP gene) or Tac1 (SP gene ; Fig 4, E) . In contrast, IL-31 increased Nppb mRNA levels by approximately 2-fold. Altogether, these findings confirm that IL-31 directly induces BNP release and upregulates its synthesis, indicating BNP might contribute to IL-31-mediated itch signaling.
Subsequently, we performed immunofluorescence studies using antibodies against BNP or CGRP with their specificities verified (see Fig E3 in . Nppb is upregulated in sensory ganglia from HDM-treated Grhl3PAR2 /1 mice and IL-31Tg mice. A, FPKM values for Nppb, NPR1, NPR2, IL-31, IL31RA, and OSMR genes from TGs of ipsilateral (ipsi) versus contralateral (contra) were analyzed by using RNA-Seq and compared. Eight mice were treated with HDM on the right cheek and nothing on the left cheek, and the cheek biopsy specimens were scored clinically by using H&E staining. The correlation coefficient between clinical score and fold change of Nppb is about 0.8, whereas for other genes analyzed, values are not significant. For these 8 mice, the average fold change of Nppb is 2.3. B, Representative H&E staining images show the severity of skin lesions from HDM-treated mice compared with vehicle-treated WT control mice. Images were taken by using a 310 magnification objective. C, FPKM values analyzed by using RNA-Seq of the top 3 high clinical scores (scores were 8, 7, and 7) show the Nppb gene was upregulated by 3.5 times (ipsilateral vs contralateral). Average fold change for genes upregulated and reaching significance were plotted. A 2-fold change in FPKM value was deemed significant. D, RT-PCR analysis of Nppb mRNA levels in DRGs isolated from lesional and nonlesional IL-31Tg or WT mice. Values were normalized to the housekeeping gene GAPDH. Results (means 6 SEMs) are pooled data from multiple animals. Significant differences are indicated as follows: *P < .05 and **P < .01.
both CGRP
1 and CGRP 2 neurons (Fig 4, F) . This distinct but overlapping distribution suggests that BNP and CGRP can have discrete functional roles in transduction of itch signaling.
IL-31 induces BNP release from cultured mDRGs through SNARE-mediated vesicle fusion
BNP release from sensory neurons in response to itch stimuli might be regulated by selective exocytotic machinery. In terms of IL-31-induced BNP release, its mechanism is of particular importance because of its relevance in patients with AD. SNAREs are critical membrane fusion proteins and serve as therapeutic targets for many neurological diseases. 26 To explore their role in BNP release, synaptosomal-associated protein 25k (SNAP-25) and 2 other vesicular SNARE proteins, vesicle-associated membrane protein (VAMP) isoforms 1 (V1) and 7 (V7), were selectively knocked down by using lentiviral shRNA particles. Notably, expression levels of each protein were reduced substantially compared with nontargeted control levels (Fig 5, A) . Knockdown of SNAP-25 and V1, but not V7, resulted in complete blockade of IL-31-elicited BNP release (Fig 5, B) . For the first time, these findings demonstrated that selective SNARE proteins control IL-31-induced BNP release.
Expression of BNP and its receptors is increased in the skin of patients with AD
To understand BNP-induced signaling and identify the functional consequence of BNP in human skin, we examined the expression of BNP and its receptors, NPR1 and NPR2, in cultured hKCs. Using immunostaining, we readily detected expression of NPR1 and NPR2 in cultured hKCs (see Fig E4, A, in this article's Online Repository at www.jacionline.org). Both receptors showed punctate distribution. In great contrast, the BNP immune signal was less than the detection limit in these cultured cells (see Fig E4, A) .
Next, similar experiments were performed on human skin sections from patients with AD and healthy control subjects. We (Fig 4, A) , CGRP, and SP (Fig 4, D) over 30 minutes was measured based on specific ELISAs or EIAs, and the increment of release after each treatment was plotted relative to the basal level. The amount in picograms per milliliter in basal (LK) release is 15.3 6 1.2 for BNP, 3.9 6 0.9 for SP, and 49.3 6 11.8 for CGRP. HIS, Histamine; HK, high-potassium stimulation buffer; LK, low-potassium basal buffer. B, BNP release induced by various doses of IL-31 over 30 minutes. C, Time dependence of BNP release induced by 300 nmol/L IL-31. E, RT-PCR for mRNA of Nppb, Calca, and Tac1 in cultured mDRGs after treatment with 100 ng/mL IL-31 for 6 hours. Data in Fig 4, A-E, are presented as means 6 SEMs (n > _ 3 independent experiments). Significant differences are indicated as follows: N.S., P > .05; *P < .05; **P < .01; and ***P < .001. HIS, Histamine. F, Immunofluorescence study for cellular localization of CGRP (red) and BNP (green) after dual labeling of DRGs with each specific antibody and counterstained with 49,6-diamidino-2-phenylindole (DAPI; blue). Scale bars are as indicated.
J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 5 found that in the epidermis no BNP staining was discernible in normal skin, similar to the observation in cultured keratinocytes, but it was readily detected in the skin of patients with AD (Fig 6, A) , indicating a disease-related upregulation of BNP expression. We also detected immune signals of NPR1 and NPR2 in the epidermal keratinocytes of healthy skin (Fig 6, A) , and both signals were enhanced in AD skin (Fig 6, A) . We further analyzed the detailed distribution of these receptors by taking high-resolution confocal images in epidermal keratinocytes. Distinct localization of NPR1 and NPR2 was revealed in epidermal keratinocytes of AD skin sections. NPR1 resided predominantly along the plasma membrane of keratinocytes, whereas NPR2 was detected in both the plasmalemma and cytoplasm (Fig 6, A) . The enhanced labeling of NPR1 and NPR2 might not be simply due to the acanthosis because we did observe increased immunoreactivity at the single-KC level by using immunofluorescence staining. We further investigated BNP, NPR1, and NPR2 expression in the dermis of human skin. BNP expression was detected in the dermis of healthy skin, and its level appeared to be increased in dermal structures, including the secretory portion of sweat glands and blood vessels of AD skin (Fig 6, B) . Interestingly, NPR2 (Fig 6, C, left panel) and NPR1 (data not shown) did not seem to colocalize with PGP9.5 in these structures. NPR1 and NPR2 co-occurred on the dermal structures, including the secretory portion of sweat glands and blood vessels (Fig 6, C,  middle and right panels) . There was no obvious incremental labeling of NPR1 or NPR2 in the dermal structures (Fig 6, C) and immunoreactive cells in AD skin compared with healthy skin (see Fig E5 in this article' s Online Repository at www.jacionline.org).
Consistently, using RT-PCR, we also found Nppb transcripts were upregulated in lesional and nonlesional skin compared with that in WT skin (see Fig E6, A, in this article's Online Repository at www.jacionline.org). Moreover, BNP receptor NPR1 mRNA levels were also increased in the lesional skin of IL-31Tg mice (see Fig E6, B) .
Taken together, these collective data suggest that BNP might be involved in promoting the dermatitis response through activated/upregulated receptor in patients with AD.
BNP induces release of IL-17A, CXCL10, and matrix metalloproteinase 9 from cultured human keratinocytes through activation of glycogen synthase kinase 3 > c-Jun N-terminal kinase > extracellular signal-regulated kinase 1/2 > _ p38
Keratinocytes of patients with AD exhibit a propensity to produce exaggerated cytokines, chemokines, and proteases, which play major role in promoting and maintaining inflammation. 27, 28 However, nothing is known about the influence of BNP on hKCs. We first investigated the possible BNP effect on hKCs. Cells in culture were exposed to BNP for 24 hours before , and NPR2 in AD and healthy control skin. Note that the epidermal keratinocyte layer of AD skin showed enhanced staining of BNP, NPR1, and NPR2 compared with healthy control skin. Boxed areas in middle panels are shown at higher magnification in right panels. B, Images show increased BNP staining in dermal structures, including secretory portions of sweat glands and blood vessels in AD skin compared with healthy skin. C, NPR2 does not colocalize with the nerve marker PGP9.5 in dermal structures but shows high colocalization with NPR1. There is no obvious change in NPR1 and NPR2 expression in the dermis between skin of patients with AD and healthy control skin. Scale bars are as indicated. Paraffin-embedded human skin sections (n 5 10) from each donor of patients with AD and healthy control subjects were stained for each condition. White lines denote epidermal-dermal junctions. DAPI, 49,6-diamidino-2-phenylindole.
J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 5 supernatants were collected and used for the proteome profiler human XL cytokine array, which allowed detection of 102 different cytokines simultaneously. An increase in IL-17A (approximately 2.5-fold), CXCL10 (approximately 2-fold), and, to a lesser degree, matrix metalloproteinase 9 (MMP9) levels was detected in culture supernatants (Fig 7, A) . In contrast, significantly lower levels of cytokine release were triggered by the same dose of SP. In comparison, incubation of hKCs with 1 mmol/L human CGRP peptide for 24 hours induced only minimal CXCL5 release (Fig 7, A) . IL-17A is a critical cytokine involved in the pathogenesis of AD. 29, 30 Its expression in keratinocytes was reported [31] [32] [33] and detected in our primary culture (see Fig E4, B) . CXCL10 mediates cell adhesion, migration, and inflammatory infiltrates in patients with AD. 34 Increased levels of IL-17A and CXCL10 are implicated in patients with AD. 28, 29, 35 Thus peripheral BNP might promote release of itch-related cytokines by acting on keratinocytes to propagate itch signals in patients with AD.
Subsequently, we investigated the signaling pathways involved in keratinocyte activation by using phosphokinase arrays on cell lysates of hKCs harvested after exposure to 1 mmol/L human BNP for 8 minutes. Glycogen synthase kinase 3 (GSK3), c-Jun N-terminal kinases (JNK; JNK kinase family includes 3 proteins named JNK1, JNK2, and JNK3), extracellular signal-regulated kinase 1/2, and p38 were significantly phosphorylated/activated by application of BNP. In contrast, extracellular signal-regulated kinase 1/2, JNK, and, to a lesser extent, GSK3 were activated by SP (Fig 7, B) .
IL-17A is considered a potent stimulator of further inflammatory mediator production, amplifying the inflammatory response. Therefore, by using selective phosphokinase inhibitors, we investigated which intracellular kinase was responsible for the BNP-mediated IL-17A release from hKCs. The p38a inhibitor AL8697, GSK3 inhibitor SB216763 (inhibiting the activity of a and b isozymes of GSK3), or JNK inhibitor JNK-IN-8 (all at 1 mmol/L) were incubated with cultured hKCs for 1 hour before and during 24 hours of incubation with BNP before measuring IL-17A release with the IL-17A ELISA kit. Inhibition of GSK3 by SB216763 abolished IL-17A release, whereas AL8697 produced only minor blockade (Fig 7, C) . Because IL-17A is regarded as a key cytokine involved in the pathogenesis of AD, 36, 37 targeting GSK3 might prove effective for inhibition of itch transmission.
BNP stimulates release of CCL20 through c-Jun activation in monocyte-derived hDCs
We then assessed a possible functional consequence of BNP on hDCs, skin immune cells known to express BNP receptors. 38 To do this, monocyte-derived hDCs were maintained in the presence of IL-4 and GM-CSF to allow their differentiation before incubating with 1 mmol/L human BNP for 24 hours. We found CCL20 release was increased significantly by BNP, and this was not observed when incubated with 1 mmol/L SP (Fig 7, D) . In the phosphokinase array BNP also activated cJun through phosphorylation, unlike SP, which did not show any effect on c-Jun activation (Fig 7, E) . CCL20 levels are strongly increased in lesional skin tissue of patients with AD, and this increase stimulates migration of various immune cells. [39] [40] [41] Thus BNP induction of CCL20 release might MMP9 IL-17A  CXCL10  CXCL5  MMP9  IL-17A  CXCL10  CXCL5  MMP9  IL-17A  CXCL10  CXCL5  MMP9  IL-17A  CXCL10  CXCL5 . Significance between stimulated and basal values is indicated as follows: *P < .05, **P < .01, ***P < .001.
constitute a novel neuron immunomodulatory mechanism that results in activation of immature dendritic cells, which could contribute to the persistent itch.
DISCUSSION
Patients with AD experience a ''vicious cycle of itching and scratching.'' 42 However, the molecular basis for this phenomenon is still unknown. Although it has been revealed recently that cytokines such as IL-31 and IL-4 or IL-13 play a role in immunity and itch transmission, 8, 43, 44 it is currently unknown whether cytokines like IL-31 also regulate neuropeptide release from peripheral nerve endings, thereby modulating neurogenic inflammation in patients with AD (Fig 8) . Understanding the importance of neuropeptide-and cytokine-mediated intercellular communication would further explain not only the interplay between inflammation and itch but also how this debilitating symptomatology of inflammation and itch can be therapeutically interrupted. Here, for the first time, we show that peripherally released BNP is implicated in AD pathophysiology through IL-31 stimulation and subsequent regulation of cytokine, chemokine, and MMP9 release. Moreover, we show that BNP also activates several major cell types in skin that are pivotal in AD itch transmission, such as keratinocytes and dendritic cells (Fig 8) . Thus we have revealed another mechanism of how T H 2 cells simultaneously affect itch and neuroinflammation.
BNP was originally identified as an important contributor of central itch because it is released from central primary afferents to the dorsal horn of the spinal cord. 19 Here, for the first time, we show that BNP is released from peripheral nerve endings on stimulation by pruritogens, such as IL-31 and histamine. These findings provide a new link between T H 2 cells, mast cells, and peripheral sensory nerves. Notably, this is unique to BNP as to other neuropeptides, such as CGRP and SP, because neither are synthesized or released under the same conditions, despite both being linked to itch. 45, 46 In addition, BNP and its receptor, NPR1, are expressed in CGRP 1 small sensory neurons. 47 In fact, although traditionally viewed primarily as a pain mediator, 48 SP has also been implicated as an itch mediator in patients with AD, with increased numbers of SP 1 nerve fibers found concomitantly with a decrease in cutaneous SP levels in lesional skin of patients with AD 49, 50 and responsiveness to the neurokinin 1 receptor antagonist aprepitant. 45, 51 In particular, BNP-expressing sensory neurons are found not to be involved in acute, inflammatory, or neuropathic pain, 19, 52 unlike SP and CGRP. Therefore our findings further differentiate BNP from CGRP and SP and highlight its importance in the neuropeptide-mediated pathogenesis of AD-associated itch.
Here, for the first time, we show that IL-31RA and OSMRb highly overlap in hDRGs, similar to the results observed previously in mDRGs. 53 Moreover, in hDRGs IL-31 elicited the Ca also important for several other inflammatory diseases. 54 In contrast to the minimal BNP release at resting conditions, IL-31-induced augmentation of peripheral BNP release can link to excessive itch in patients with AD induced by a positive feedback loop of amplifying itch mediators. This might also explain the difficulty of treating AD-associated itch.
Using deep sequencing, we detected upregulation of Nppb transcripts in isolated TGs from HDM-treated PAR2Tg mice, which showed AD-like skin conditions. Furthermore, our data confirm that the Nppb gene is implicated in severe AD conditions because mice with high clinical scores exhibit high levels of Nppb transcripts.
Our findings provide the first evidence showing a functional association of BNP with the severity of AD. Consistently, we established that Nppb transcripts in DRGs and skin of lesional IL31Tg mice were also greatly upregulated. NPR1 transcripts were increased in lesional IL-31Tg skin. In fact, upregulation of BNP in murine AD-like skin has also been reported by a recent finding using the global transcriptome, which identified a significant Nppb upregulation (>3-fold) in skin of oxazolone-challenged mice with AD-like dermatitis. 55 In a translational approach we also provide evidence for the importance of BNP in patients with AD by using skin from patients with AD and healthy control subjects. We detected increased protein levels of NPR1 and NPR2 in the epidermis, particularly in keratinocytes. Moreover, enhanced expression of BNP in both the epidermis and dermis of patients with AD was revealed. In fact, immunostaining signal of BNP, NPR1, and NPR2 protein seemed to be increased in single-cell levels of keratinocytes; however, we could not exclude that the possibility that acanthosis might also contribute to the increment. Upregulated expression levels of BNP and its receptors in patients with AD suggest a role for the IL-31/BNP/BNP receptor axis in peripheral itch amplification in patients with AD.
Although IL-31 rapidly induces itch in mice 7, 8 and is regarded as one of the major ''drivers'' of itch in patients with AD, it did not induce immediate itch responses in human subjects, as shown in a recent study including both patients with AD and healthy subjects monitored by using skin prick testing. 56 Although there is a possibility of insufficient amounts of IL-31 being administered that did not induce an immediate itch response, late onset of IL-31-induced mild itch sensations can also be attributed to this cytokine exerting its pruritic effect indirectly through keratinocytes and secondary mediators rather than through a sole action on its receptors on cutaneous sensory nerves. 56, 57 In addition, similar to IL-4, 44 IL-31 might be a sensitizer in some patients and not a direct itch inducer. However, variable expression levels of IL-31 and IL-31RA in patients with AD might explain that some patients will respond more to IL-31 stimulation. Consequently, some patients can profit better from anti-IL-31 therapy than others. 11, 12 It will be interesting to learn whether IL-4 and IL-13 are also linked to BNP release.
We demonstrate that BNP acts as the downstream skin-derived effector of IL-31. In addition to its contribution to spinal processing of itch, 19 excessive release of BNP from peripheral sensory nerves stimulates NPR1 receptor to activate multiple intracellular signaling pathways in the skin, thereby contributing to skin inflammation in patients with AD. We found that BNP activates the GSK3 pathway and leads to secretion of several important inflammatory or itch modulators, such as IL-17A, CXCL10, or MMP9, from skin keratinocytes. BNP activates c-Jun to release CCL20 from DCs. Levels of all of these cytokines are known to be increased in patients with AD and represent an important potential component of the pathology of AD. 58, 59 Upregulation of BNP receptors, in turn, could further augment secretion of the above important itch modulators from these cells. Thus our results support a new pathway in which BNP is a peripheral contributor of IL-31-mediated neurogenic inflammation in patients with AD and establishes the missing link between T H 2 nerve-mediated inflammation and pruritus.
In conclusion, we describe a novel functional link between T H 2 cells and sensory nerves through IL-31 and BNP and provide the first evidence between a functional association of peripheral BNP in AD using human and rodent DRGs, animal models, and patient skin in a translational fashion. Indeed, T H 2 cells, sensory neurons, keratinocytes, and dendritic cells release a complex network of cytokines and chemokines establishing a local milieu and environment that favors AD skin inflammation. In this context BNP seems to act as an important ''relay center'' for peripheral and central itch circuits to facilitate both itch and neuroinflammation in the pathogenesis of AD. We demonstrate that BNP acts through multiple mechanisms: (1) IL-31 modulates pruriceptive neurons to rapidly induce SNARE-dependent release of BNP; (2) IL-31 increases Nppb synthesis; (3) BNP receptors are upregulated in patients with AD; and (4) BNP signals through its upregulated receptors to directly activate multiple intracellular kinases in skin cells to elicit the release of itch-related proinflammatory cytokines (Fig 8) . Our findings provide new insights about BNP as an important regulator of neuroinflammation, as well as itch, in the skin of patients with AD, and close a missing link about why the itch-related inflammatory skin disease AD has been also defined as neurodermatitis. In addition, peripheral BNP signaling provides a new basis for the development of more effective therapies for AD and probably other skin diseases.
Key messages
d IL-31 induces SNARE-dependent BNP release and its synthesis in sensory nerves.
d BNP increases AD-related cytokine release from keratinocytes and dendritic cells through GSK3-dependent and cJun activation pathways, respectively.
d AD is associated with upregulation of BNP and its receptor.
METHODS Materials
Skin samples from patients with AD and healthy control subjects were bought from Tissue Solutions. EIA kits for CGRP and SP were bought from Bioquote (York, United Kingdom); rabbit anti-syntaxin 1, anti-VAMP1, and anti-VAMP7 were bought from Synaptic Systems GmbH (G€ ottingen, Germany). SP, BNP, CGRP, histamine, and ET-1; mAb specific for CGRP (4901); rabbit anti-PGP9.5; ELISA kit for BNP; and shRNA lentiviral particles were bought from Sigma-Aldrich (St Louis, Mo). Donkey anti-rabbit Alexa Fluor 488 and anti-mouse Alexa Fluor 594, donkey anti-goat Alexa Fluor 594, and anti-mouse Alexa Fluor 488 were supplied by Jackson ImmunoResearch, (West Grove, Pa). Ibidi GmbH (Planegg, Germany) provided culture chambers. Rabbit anti-BNP antibody (G-011-23) was purchased from Phoenix Pharmaceuticals (Burlingame, Calif), and monoclonal anti-SNAP-25 (SMI 81) was bought from Sternberger Monoclonals (Baltimore, Md). Mouse monoclonal anti-PGP9.5 (Ab8189), anti-NPR2 (Ab55724), rabbit anti-NPR1 (Ab14356), anti-BNP (Ab19645), and anti-NeuN (Ab177487) antibodies and an IL-17A ELISA kit were provided by Abcam (Cambridge, United Kingdom). AL8697, goat anti-IL-31RA, mouse anti-OSMRb, CCL20 ELISA kit, proteome profiler human XL cytokine array, human phosphokinase array kits, and IL-17A antibody (AF-317-NA) were bought from R&D Systems (Minneapolis, Minn). SB216763 was purchased from Tocris Bioscience (Bristol, United Kingdom). JNK-IN-8 was obtained from Axon Medchem (Reston, Va). Rabbit anti-NPR1 antibody (NBP1-31333) was purchased from Novus Biologicals (Littleton, Colo). Adult normal hKCs and hDCs and their culture medium were bought from Lonza. hDRG paraffin sections were bought from Zyagen. Alexa Fluor 594-conjugated mouse anti-human vimentin antibody, Alexa Fluor 488-conjugated mouse anti-human CD4, and Alexa Fluor 488-conjugated mouse anti-human CD80 were purchased from BioLegend (San Diego, Calif). Mouse C57 DRG sections were purchased from Amsbio.
HDM application in the Grhl3PAR2
/1 mouse model Grhl3PAR2 /1 mice were maintained in the C57BL6/J-129X1/SvJ mixed strain and used for experiments as an AD model. We used mite extract ointment/HDM (BiostirAD catalog no. 303-34131) on the right cheek to induce severe skin lesions. For HDM treatment, 8 mice were shaved on the cheek 1 day before application. On the application day, 4% SDS was rubbed on the shaved cheek area 2 hours before HDM application. HDM was applied on the right cheek twice a week with at least a 3-day resting period before the next application for 6 weeks. At the end of the treatment, we killed the mice and harvested lesional, perilesional, and nonlesional skin for pathologic diagnosis using H&E staining to measure the clinical score, and TGs were harvested for gene expression experiments. 
FIG E5.
Immunohistochemical dual staining of NPR1 and NPR2 in skin of a human healthy control subject and a patient with AD. Representative fluorescent images at low (left column panels) and high (right column panels) magnification of NPR1 and NPR2 in skin of a healthy control subject (A) and a patient with AD (B). NPR1 and NPR2 are highly localized in some cells in the dermis. Specimens were counter-stained with 49,6-diamidino-2-phenylindole (DAPI).
